The Global head & neck cancer drugs market was valued at US$ 1.16 Billion in 2020 and is expected to reach US$ 2.98 Billion by 2030, growing at a CAGR of 9.6% from 2021 – 2030.
Head & neck cancer is a term used to define different malignant tumors that develop from tissues in the oral cavity, throat, nose, sinuses, salivary glands, and skin of the face. Most of the head & neck cancers are squamous cell carcinomas. If cancer is found only in the squamous layer of cells, it is called carcinoma in situ. If cancer has grown beyond this cell layer and moved into the deeper tissue, then it is called invasive squamous cell carcinoma. Symptoms of head & neck cancer include sore throat, unusual bleeding, numbness, swelling, facial pain, and visible lumps. In rare cases, the patient has trouble breathing as well. The core reason for head & neck cancer is excessive consumption of alcohol and tobacco, increasing cases linked to human papillomavirus, prolonged sun exposure, poor dental and oral hygiene, poor nutrition, and inappropriate occupational & environmental inhalants. Prevention measures include avoiding alcohol, smoking, using sunscreen reducing risks of HPV infection, and maintaining dentures. Drugs such as Pembrolizumab (Keytruda) by Merck & Company and Nivolumab (Opdivo), developed by Bristol-Myers Squib are further augmenting the market growth vigorously.
FDA-approved drugs such as Bleomycin Sulphate, Cetuximab, Docetaxel, Erbitux, Hydroxyurea, Methotrexate Sodium, Nivolumab, Opdivo, Pembrolizumab, and Trexall are the major drugs augmenting the market growth of the global head & neck cancer drugs market.
High prevalence of head & neck cancer globally, technological advancements in the diagnosis & screening of cancer, and rise in the demand for combination therapy for the treatment are driving the global head & neck cancer drugs market. Side effects especially in chemotherapy, the healthy cells of the patient are harmed along with the malignant cells, and these factors are highly restricting the market growth. However, Increased R&D activities in the therapeutic sector coupled with novel pipeline drugs such as Atezolizumab, Ipilimumab, Avelumab, Erlotinib, Durvalumab, Afatinib, Bevacizumab, and others. The consumption of alcohol & tobacco in an excessive manner is further leading to increased cases of head & neck cancer hence pouring the growth of the global head & neck cancer drugs market growth.
The global head & neck cancer drugs market is fragmented into Drug class, Sales Channel, and Region. By Drug class, the global market is bifurcated into Chemotherapy, Immunotherapy, and Targeted therapy. Chemotherapy segmented dominated the global market among the Drug Class segment owing to its high usage during radiation therapies. bleomycin, cetuximab, docetaxel, paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are the most effective available drugs among others. Based on Sales channel, the global market is classified into Hospital Pharmacies, Drug stores & Retail pharmacies, and Online stores. Drug stores & retail pharmacies are dominating the global market owing to their high presence in the market. The online stores segment is expected to foresee high growth during the forecast period.
Based on Region, the global head & neck cancer drugs market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is further classified into the U.S., Canada, and Mexico. Europe is further segmented into Germany, the U.K., France, Italy, Spain, Russia, and the rest of Europe. Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of APAC. The RoW includes South & Central America, the Middle East, and Africa. Currently, APAC is dominating the global market among all the geographies owing to the key market players, high prevalence of head & neck cancer, and high consumption of tobacco & alcohol in the region.
Prominent players of the global head & neck cancer drugs market are Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company (ARMO Biosciences), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), AstraZeneca PLC, Immutep Limited, Novartis AG, Merck KGaA (EMD Serono, Inc.), Pfizer Inc., and Merck & Co., Inc., among others.
Market Segmentation and Scope of the Global Antifungal Drug Market